Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Patient Insights into the Design of Technology to Support a Strengths-Based Approach to Health Care.

Greater intake of dietary omega-3 fatty acids associated with lower risk of diabetic retinopathy

SURVEY: Weight Management & Chronic Illness

Japanese green tea consumers have reduced risk of dementia

Researchers find herpes strain in the nervous system

Do Nothing, Accomplish Everything! The Connection Between Breathing and Healing

Nature Heals

Best Herbs to Help With Insomnia

Choline: Why You Should Eat Your Egg Yolks and Take Krill

Calcium, vitamin D supplementation associated improved stroke recovery

 
Print Page
Email Article

Positive Findings Presented on Celebrex® Safety and Tolerability

  [ 5 votes ]   [ Discuss This Article ]
By News Release • www.ProHealth.com • April 17, 2000


SUMMARY: Long-term safety studied in major organ systems, at 4 times the Osteoarthritis dose -- Ibuprofen and diclofenac found to cause significantly greater GI blood loss than Celebrex.

CHICAGO, April 17 /PRNewswire/ -- In a landmark study to assess the overall long-term safety of the COX-2 specific inhibitor Celebrex® (celecoxib capsules), arthritis patients taking four times the recommended osteoarthritis (OA) dose of the drug experienced fewer symptomatic gastrointestinal (GI) ulcers and ulcer complications than patients taking ibuprofen and diclofenac -- a difference that was statistically significant based on a combined analysis of Celebrex versus these two traditional nonsteroidal anti-inflammatory drugs (NSAIDs). The findings, presented at the American College of Physicians annual meeting, also demonstrated differences on a variety of measures in renal and liver toxicity among those taking Celebrex or the NSAID comparators, two of the world's most widely prescribed drugs of this kind. Importantly, Celebrex showed no increase in thromboembolic or other cardiovascular-related events, even among non-aspirin users.

Also, in comparison to Celebrex, ibuprofen and diclofenac were associated with a significantly greater GI blood loss -- equivalent to two pints or more -- over the course of the study, even in patients not experiencing bleeding ulcers. Such blood loss can often signal serious hidden damage throughout the GI tract.

Groundbreaking Study Reflects Real-World Practice
The Celecoxib Long-term Arthritis Safety Study, an approximately 13-month, multi-center, randomized, double-blind outcomes trial of about 8,000 arthritis patients -- 5,800 with OA and 2,200 with rheumatoid arthritis (RA) -- was designed to mirror everyday clinical practice by enrolling a broad spectrum of patients, including adult patients of all ages and disease severity, and patients taking low-dose aspirin for cardioprotection. The study, designed to obtain a rigorous assessment of Celebrex safety, compared four times the recommended OA dose of Celebrex (800 mg daily) to typical daily doses of ibuprofen (2400 mg daily) and diclofenac (150 mg daily). The Celebrex study dose is twice the highest recommended RA dose.

"No previous study has examined such a broad range of GI side effects -- which encompass events ranging from serious and often devastating GI ulcers and ulcer complications, to silent but medically important damage to the lining of the intestine, to symptoms like abdominal pain," said Lee S. Simon, M.D., associate professor of medicine, Harvard Medical School. "We've known the serious risks of traditional NSAIDs for some time, but these long-term findings show that patients taking Celebrex, in contrast to those on ibuprofen or diclofenac, experienced fewer treatment-related side effects in a number of important areas. These side effects often limit patients' ability to maintain their therapy and get the arthritis pain relief they require."
Researchers estimate that up to 30 percent of patients taking traditional NSAIDs develop persistent GI symptoms, and more than 10 percent of all patients discontinue treatment.(1) An estimated 33 million people take traditional NSAIDs regularly. (2)
The study, funded by Searle and Pfizer Inc, found that Celebrex patients experienced significantly fewer symptomatic GI ulcers and ulcer complications compared with ibuprofen or diclofenac. Celebrex was also associated with numerically fewer ulcer complications than the NSAID comparators among all patients, and 64 percent fewer of these serious events among non-aspirin users -- a statistically significant difference. It is well known that aspirin is an independent risk factor for GI complications. Ulcer complications typically lead to
hospitalization, and in some cases, death. Further, patients in the study reported Celebrex to be well tolerated, with dyspepsia, nausea and abdominal pain occurring at a significantly lower rate than with diclofenac.

"This rigorous outcomes trial set the bar higher than any previous study of its kind. It included a large number of patients who received four times the recommended OA dose of Celebrex for up to 13 months. It also compared Celebrex with commonly used traditional NSAIDs -- ibuprofen, one of the most well tolerated; and diclofenac, extensively used throughout the world," said Fred Silverstein, M.D., chairperson of the study's external review board. "Even at these very high doses, Celebrex showed sustained safety and tolerability in organ systems often affected by NSAIDs. As such, these are compelling findings for physicians to consider when treating arthritis patients."

Beyond GI Events: Safety Results in Major Organ Systems
In addition, the study examined the renal, liver and cardiovascular safety profile of Celebrex. Observed rates of various renal abnormalities and renal complications among Celebrex-treated patients were significantly lower as compared with diclofenac and ibuprofen, respectively. Moreover, in this study, significantly more patients developed hypertension or edema on ibuprofen, and kidney or liver abnormalities on diclofenac, compared to the Celebrex group. Furthermore, Celebrex showed no increases in thromboembolic events (such as myocardial infarctions and stroke) or other cardiovascular adverse events compared with the traditional NSAID comparators. This is an important finding in light of the fact that about 40 percent of patients in each arm of the study had a history of cardiovascular disease, and about half of these patients were taking low-dose aspirin.

The incidence of skin rash was significantly higher with Celebrex -- at four times the recommended OA dose -- compared with both of the traditional NSAIDs. No serious rashes were observed. Other adverse events most commonly reported with Celebrex in these studies, at approximately the same rate as the comparators, included colds and sinusitis.
Many of the estimated 43 million Americans(3) with OA and RA use NSAIDs, which can lead to stomach ulcers and other serious complications, and are the greatest source of serious adverse drug reactions reported to the U.S. Food and Drug Administration(4). These GI side effects often show no obvious signs or symptoms and go undiagnosed until patients are admitted to the hospital emergency room. Typically 60 to 80 percent of GI complications resulting from NSAIDs occur without previous symptoms.(5),(6)

Patients who have a known allergic reaction to celecoxib, certain sulfa drugs called sulfonamides, aspirin or NSAIDs should not use Celebrex. As with all NSAIDs, serious GI tract ulcerations can occur without warning symptoms. Physicians and patients should remain alert to the signs and symptoms of GI bleeding. Concomitant administration of aspirin with Celebrex may result in an increased risk of GI ulceration or other complications, compared to Celebrex alone. Celebrex does not affect platelet function and therefore should not be used for cardiovascular prophylaxis. As with all NSAIDs, Celebrex should be used with caution in patients with fluid retention, hypertension, or heart failure. In studies, the most common side effects of Celebrex were dyspepsia, diarrhea and abdominal pain, which were generally mild to moderate.

(1) Singh G, Ramey DR, NSAID induced gastrointestinal complications: the
ARAMIS perspective -- 1997. J Rheumatology, 25 (suppl 51), 1998,
pp. 8-16.
(2) Roper Starch Worldwide NSAID Risk Survey, January 1998. [Statistic
projected from survey: 33 million Americans use NSAIDs to relieve any
kind of pain on at least two occasions within 12 months for at least
five consecutive days.]
(3) National Arthritis Action Plan, AF, ASTHO, CDC, 1999.
(4) SRI International, February 1997.
(5) Armstrong and Blower. Gut. 1987;28:527-532.
(6) Singh et al. Archives of Internal Medicine. 1996; 156:1530-1536.

Sources: Searle and Pfizer Inc



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Ultra EPA  - Fish Oil Ultra ATP+, Double Strength

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Physically and Mentally Exhausted? How to Restore Energy at Its Source Physically and Mentally Exhausted? How to Restore Energy at Its Source
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
Quercetin: Natural Support for Allergy & Inflammation Relief and More Quercetin: Natural Support for Allergy & Inflammation Relief and More

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map